China Molybdenum subsidiary commits 500m yuan to investment fund

Luoyang Molybdenum Co., Ltd. (China Molybdenum) announced on December 1, 2025, that its wholly-owned subsidiary, Tibet Shamrock Trading Co., Ltd., signed a limited partnership agreement to subscribe for 500m yuan in fund units of Boyu Xinzhi New Product (Ningbo) Equity Investment Partnership (Limited Partnership). The fund will primarily focus on investments in technology, healthcare, consumer goods, and retail.

The transaction was approved by China Molybdenum's board of directors on December 1, 2025. This transaction is considered a related party transaction because Contemporary Amperex Technology Co., Limited (CATL), which is also investing in the fund, indirectly holds 24.91% of China Molybdenum’s shares. However, it does not constitute a major asset reorganization. Independent directors unanimously approved the proposal, deeming it beneficial for capital utilization and shareholder returns.

The fund is yet to be registered with the Asset Management Association of China, and its subsequent fundraising and investment progress remain uncertain. The investment carries risks, including potential inability to achieve expected returns, challenges in timely exit, and uncertainties influenced by policy, macroeconomic conditions, and industry cycles.